Andrew J Wagner

28PUBLICATIONS
180CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursPharmacogenomicsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Aug 26, 2026
Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

|Jul 06, 2026
Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

|Jun 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

|Jul 04, 2025
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.

Andrew J Wagner, William D Tap, Sebastian Bauer

|Dec 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.

J Andrew Livingston, Jean-Yves Blay, Jonathan Trent

|Nov 12, 2024
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.

Jayesh Desai, Andrew J Wagner, Irene Carrasco Garcia

Pageof 5

Frequent Collaborators

8 joint publications

Jean-Yves Blay

7 joint publications

Silvia Stacchiotti

5 joint publications

Brian A Van Tine

5 joint publications

Javier Martín-Broto